The use of agents that act on the renin–angiotensin–aldosterone system, SGLT2 inhibitors, GLP-1 receptor agonists, and a nsMRA (finerenone) are described as the four pillars of treatment to reduce cardiorenal outcomes in people with T2D and CKD [Supplementary reference 33]. The gene discussed is REN; the disease is type 2 diabetes mellitus.